OTLK Outlook Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649989 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-40.7%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin195.6%
Operating margin4,781.8%
Net margin5,253.5%
FCF margin—
EBITDA margin4,772.9%
Returns
ROE—
ROA-251.7%
ROIC (approx.)—
Asset turnover-0.05x
Leverage & solvency
Liabilities / assets139.7%
Debt / equity—
Current ratio0.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.41M | — | — | — | — |
| Cost of revenue | $1.36M | — | — | — | — |
| Gross profit | $57,205 | — | — | — | — |
| R&D expense | $27.18M | $41.76M | $26.45M | $42.33M | $38.96M |
| SG&A expense | $39.94M | $29.94M | $26.67M | $20.74M | $12.77M |
| Operating income | -$67.06M | -$71.70M | -$53.13M | -$63.07M | -$51.73M |
| Interest expense | — | $3.16M | $2.53M | — | — |
| Pretax income | -$63.98M | -$75.36M | -$58.98M | -$66.05M | -$53.16M |
| Income tax | -$1.55M | $2,800 | $2,800 | $2,800 | $2,000 |
| Net income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M |
| EBITDA | -$66.94M | -$71.59M | -$53.08M | -$62.87M | -$51.46M |
| EPS (basic) | -1.79 | -4.06 | -4.72 | -0.31 | -0.35 |
| EPS (diluted) | -1.79 | -4.06 | -4.72 | -0.31 | -0.35 |
| Weighted avg. shares (diluted) | 34.80M | 18.55M | 12.51M | 212.08M | 152.68M |
| Banking | |||||
| Net interest income | -$283,128 | -$3.16M | -$1.56M | -$1.49M | -$936,127 |
| Balance sheet | |||||
| Cash & equivalents | $8.08M | $14.93M | $23.39M | $17.40M | $14.48M |
| Receivables | $1.49M | — | — | — | — |
| Inventory | $3.34M | — | — | — | — |
| Current assets | $17.39M | $27.42M | $30.98M | $27.52M | $21.51M |
| PP&E, net | — | — | — | — | $163,625 |
| Total assets | $18.58M | $28.82M | $32.30M | $28.53M | $22.81M |
| Current liabilities | $45.81M | $42.55M | $46.73M | $19.73M | $6.75M |
| Total liabilities | $50.77M | $101.90M | $46.74M | $19.79M | $18.20M |
| Shareholders' equity | -$32.19M | -$73.08M | -$14.44M | $8.74M | $4.61M |
| Shares outstanding | 53.89M | 23.91M | 13.01M | 227.31M | 176.46M |
| Cash flow statement | |||||
| Operating cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | -$54.25M |
| Financing cash flow | $44.98M | $60.33M | $48.97M | $59.59M | $56.19M |
| Depreciation & amortization | $117,052 | $113,859 | $44,188 | $204,694 | $262,140 |
| Stock-based compensation | $8.90M | $5.39M | $5.55M | $7.71M | $4.89M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.